article · Nanomedicine
AIMS: Malaria remains a major global health burden, particularly in sub-Saharan Africa. Although quinine (QN) is an effective antimalarial, its clinical application is limited by dose-dependent toxicity from nonspecific biodistribution. This study developed heparin-functionalized PCL nanoparticles (Hep-QN-PCL) to target Plasmodium falciparum-infected RBCs and enhance QN's therapeutic efficacy. METHODS: drug release, hemolysis, cytotoxicity, targeting, and antiplasmodial activity against FCR3 Plasmodium falciparum. RESULTS: = 23.33 ng/mL vs. 122.86 ng/mL) and 14.2-fold greater selectivity index (22.60 vs. 1.59). CONCLUSION: These findings demonstrate a targeted nanomedicine platform with improved efficacy and safety for malaria therapy, suitable for further preclinical studies.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/17435889.2026.2658589
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.